A citation-based method for searching scientific literature

Alejandro Correa-Sáez, Rafael Jiménez-Izquierdo, Martín Garrido-Rodríguez, Rosario Morrugares, Eduardo Muñoz, Marco A Calzado. Cell Mol Life Sci 2020
Times Cited: 11







List of co-cited articles
127 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.
Naoe Taira, Rei Mimoto, Morito Kurata, Tomoko Yamaguchi, Masanobu Kitagawa, Yoshio Miki, Kiyotsugu Yoshida. J Clin Invest 2012
93
72

Multiple functions of DYRK2 in cancer and tissue development.
Saishu Yoshida, Kiyotsugu Yoshida. FEBS Lett 2019
19
54

DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage.
Naoe Taira, Keishi Nihira, Tomoko Yamaguchi, Yoshio Miki, Kiyotsugu Yoshida. Mol Cell 2007
205
54

Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Sourav Banerjee, Tiantian Wei, Jue Wang, Jenna J Lee, Haydee L Gutierrez, Owen Chapman, Sandra E Wiley, Joshua E Mayfield, Vasudha Tandon, Edwin F Juarez,[...]. Proc Natl Acad Sci U S A 2019
21
54

Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition.
Meera Soundararajan, Annette K Roos, Pavel Savitsky, Panagis Filippakopoulos, Arminja N Kettenbach, Jesper V Olsen, Scott A Gerber, Jeyanthy Eswaran, Stefan Knapp, Jonathan M Elkins. Structure 2013
95
54

DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
Rei Mimoto, Naoe Taira, Hiroyuki Takahashi, Tomoko Yamaguchi, Masataka Okabe, Ken Uchida, Yoshio Miki, Kiyotsugu Yoshida. Cancer Lett 2013
53
45


Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
Xing Guo, Xiaorong Wang, Zhiping Wang, Sourav Banerjee, Jing Yang, Lan Huang, Jack E Dixon. Nat Cell Biol 2016
103
45

Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer.
Shiho Yokoyama-Mashima, Satomi Yogosawa, Yumi Kanegae, Shinichi Hirooka, Saishu Yoshida, Takashi Horiuchi, Toya Ohashi, Katsuhiko Yanaga, Masayuki Saruta, Tsunekazu Oikawa,[...]. Cancer Lett 2019
16
45

The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities.
Jacopo Boni, Carlota Rubio-Perez, Nuria López-Bigas, Cristina Fillat, Susana de la Luna. Cancers (Basel) 2020
23
45

The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress.
Rita Moreno, Sourav Banerjee, Angus W Jackson, Jean Quinn, Gregg Baillie, Jack E Dixon, Albena T Dinkova-Kostova, Joanne Edwards, Laureano de la Vega. Cell Death Differ 2021
10
50

Emerging roles of DYRK2 in cancer.
Vasudha Tandon, Laureano de la Vega, Sourav Banerjee. J Biol Chem 2021
13
45


Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs.
Pamela A Lochhead, Gary Sibbet, Nick Morrice, Vaughn Cleghon. Cell 2005
210
36

Regulation of Glioma Cells Migration by DYRK2.
Yifen Shen, Li Zhang, Donglin Wang, Yifeng Bao, Chao Liu, Zhiwei Xu, Wei Huang, Chun Cheng. Neurochem Res 2017
9
44

The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer.
Paula Moreno, Maribel Lara-Chica, Rafael Soler-Torronteras, Teresa Caro, Manuel Medina, Antonio Álvarez, Ángel Salvatierra, Eduardo Muñoz, Marco A Calzado. PLoS One 2015
14
36

Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Sourav Banerjee, Chenggong Ji, Joshua E Mayfield, Apollina Goel, Junyu Xiao, Jack E Dixon, Xing Guo. Proc Natl Acad Sci U S A 2018
66
36

DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Noriko Yamaguchi, Rei Mimoto, Nozomu Yanaihara, Yoshimi Imawari, Shinichi Hirooka, Aikou Okamoto, Kiyotsugu Yoshida. Tumour Biol 2015
28
36

Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A.
Yasushi Ogawa, Yosuke Nonaka, Toshiyasu Goto, Eriko Ohnishi, Toshiyuki Hiramatsu, Isao Kii, Miyo Yoshida, Teikichi Ikura, Hiroshi Onogi, Hiroshi Shibuya,[...]. Nat Commun 2010
176
36

ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the apoptotic response to DNA damage.
Naoe Taira, Hiroyuki Yamamoto, Tomoko Yamaguchi, Yoshio Miki, Kiyotsugu Yoshida. J Biol Chem 2010
50
36

Impairment of DYRK2 by DNMT1‑mediated transcription augments carcinogenesis in human colorectal cancer.
Tomotaka Kumamoto, Kohji Yamada, Saishu Yoshida, Katsuhiko Aoki, Shinichi Hirooka, Ken Eto, Katsuhiko Yanaga, Kiyotsugu Yoshida. Int J Oncol 2020
10
40

Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Haiyan Yan, Kaishun Hu, Wenjing Wu, Yu Li, Huan Tian, Zhonghua Chu, H Phillip Koeffler, Dong Yin. PLoS One 2016
20
27

A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT.
Yousang Gwack, Sonia Sharma, Julie Nardone, Bogdan Tanasa, Alina Iuga, Sonal Srikanth, Heidi Okamura, Diana Bolton, Stefan Feske, Patrick G Hogan,[...]. Nature 2006
286
27

Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Yuchan Wang, Yaxun Wu, Xiaobing Miao, Xinghua Zhu, Xianjing Miao, Yunhua He, Fei Zhong, Linlin Ding, Jing Liu, Jie Tang,[...]. Int J Biol Macromol 2015
11
27

A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition.
Hyeongki Kim, Kyu-Sun Lee, Ae-Kyeong Kim, Miri Choi, Kwangman Choi, Mingu Kang, Seung-Wook Chi, Min-Sung Lee, Jeong-Soo Lee, So-Young Lee,[...]. Dis Model Mech 2016
54
27

Phosphorylation-dependent regulation of the NOTCH1 intracellular domain by dual-specificity tyrosine-regulated kinase 2.
Rosario Morrugares, Alejandro Correa-Sáez, Rita Moreno, Martín Garrido-Rodríguez, Eduardo Muñoz, Laureano de la Vega, Marco A Calzado. Cell Mol Life Sci 2020
10
30

Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
Daisuke Ito, Satomi Yogosawa, Rei Mimoto, Shinichi Hirooka, Takashi Horiuchi, Ken Eto, Katsuhiko Yanaga, Kiyotsugu Yoshida. Cancer Sci 2017
20
27

DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
Wolfgang Gruber, Martin Hutzinger, Dominik Patrick Elmer, Thomas Parigger, Christina Sternberg, Lukasz Cegielkowski, Mirko Zaja, Johann Leban, Susanne Michel, Svetlana Hamm,[...]. Oncotarget 2016
43
27

A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells.
Chun Shik Park, Andrew H Lewis, Taylor J Chen, Cory S Bridges, Ye Shen, Koramit Suppipat, Monica Puppi, Julie A Tomolonis, Paul D Pang, Toni-Ann Mistretta,[...]. Blood 2019
26
27

The protein kinase complement of the human genome.
G Manning, D B Whyte, R Martinez, T Hunter, S Sudarsanam. Science 2002
27

DYRK1A autophosphorylation on serine residue 520 modulates its kinase activity via 14-3-3 binding.
Mónica Alvarez, Xavier Altafaj, Sergi Aranda, Susana de la Luna. Mol Biol Cell 2007
52
27

Characterization of a domain that transiently converts class 2 DYRKs into intramolecular tyrosine kinases.
Ross Kinstrie, Nathan Luebbering, Diego Miranda-Saavedra, Gary Sibbet, Jingfen Han, Pamela A Lochhead, Vaughn Cleghon. Sci Signal 2010
30
27


Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
Rei Mimoto, Naoe T Nihira, Shinichi Hirooka, Hiroshi Takeyama, Kiyotsugu Yoshida. Cancer Lett 2017
13
27

Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma.
Shin-ichi Yamashita, Masao Chujo, Keita Tokuishi, Kentaro Anami, Michiyo Miyawaki, Satoshi Yamamoto, Katsunobu Kawahara. J Thorac Cardiovasc Surg 2009
12
27

Multi-layered proteomic analyses decode compositional and functional effects of cancer mutations on kinase complexes.
Martin Mehnert, Rodolfo Ciuffa, Fabian Frommelt, Federico Uliana, Audrey van Drogen, Kilian Ruminski, Matthias Gstaiger, Ruedi Aebersold. Nat Commun 2020
15
27

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
Thu Lan Nguyen, Corinne Fruit, Yann Hérault, Laurent Meijer, Thierry Besson. Expert Opin Ther Pat 2017
34
27

DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives.
Fernanda Neumann, Stéphanie Gourdain, Christelle Albac, Alain D Dekker, Linh Chi Bui, Julien Dairou, Isabelle Schmitz-Afonso, Nathalie Hue, Fernando Rodrigues-Lima, Jean M Delabar,[...]. Sci Rep 2018
30
27

Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
Dnyandev B Jarhad, Karishma K Mashelkar, Hong-Rae Kim, Minsoo Noh, Lak Shin Jeong. J Med Chem 2018
50
27


Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.
R Mimoto, Y Imawari, S Hirooka, H Takeyama, K Yoshida. Oncogene 2017
19
27

Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways.
Moisés Pérez, Carmen García-Limones, Inés Zapico, Anabel Marina, M Lienhard Schmitz, Eduardo Muñoz, Marco A Calzado. J Mol Cell Biol 2012
43
27

Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
Natividad Pozo, Cristina Zahonero, Paloma Fernández, Jose M Liñares, Angel Ayuso, Masatoshi Hagiwara, Angel Pérez, Jose R Ricoy, Aurelio Hernández-Laín, Juan M Sepúlveda,[...]. J Clin Invest 2013
85
27

Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT degradation.
Hae-Yun Jung, Xin Wang, Sohee Jun, Jae-Il Park. J Biol Chem 2013
45
27

Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling.
Frank Wippich, Bernd Bodenmiller, Maria Gustafsson Trajkovska, Stefanie Wanka, Ruedi Aebersold, Lucas Pelkmans. Cell 2013
346
27


An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases.
Apirat Chaikuad, Julien Diharce, Martin Schröder, Alicia Foucourt, Bertrand Leblond, Anne-Sophie Casagrande, Laurent Désiré, Pascal Bonnet, Stefan Knapp, Thierry Besson. J Med Chem 2016
25
27

10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.
Hannes Falke, Apirat Chaikuad, Anja Becker, Nadège Loaëc, Olivier Lozach, Samira Abu Jhaisha, Walter Becker, Peter G Jones, Lutz Preu, Knut Baumann,[...]. J Med Chem 2015
54
27

Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
Tania Tahtouh, Jonathan M Elkins, Panagis Filippakopoulos, Meera Soundararajan, Guillaume Burgy, Emilie Durieu, Claude Cochet, Ralf S Schmid, Donald C Lo, Florent Delhommel,[...]. J Med Chem 2012
136
27

Role for DYRK family kinases on regulation of apoptosis.
Kiyotsugu Yoshida. Biochem Pharmacol 2008
50
27


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.